International Biotechnology (IBT) Competitors GBX 614.40 +16.40 (+2.74%) As of 11:54 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesBuy This Stock IBT vs. APEO, MUT, ESCT, TFIF, SLPE, MRCH, NBPE, AGT.LN, JESC, and SDPShould you be buying International Biotechnology stock or one of its competitors? The main competitors of International Biotechnology include abrdn Private Equity Opportunities (APEO), Murray Income Trust (MUT), The European Smaller Companies Trust (ESCT), TwentyFour Income (TFIF), Standard Life Private Equity Trust (SLPE), The Merchants Trust (MRCH), NB Private Equity Partners (NBPE), AVI Global Trust (AGT.LN), JPMorgan European Smaller Companies Trust (JESC), and Schroder Investment Trust - Schroder AsiaPacific Fund (SDP). These companies are all part of the "asset management" industry. International Biotechnology vs. Its Competitors abrdn Private Equity Opportunities Murray Income Trust The European Smaller Companies Trust TwentyFour Income Standard Life Private Equity Trust The Merchants Trust NB Private Equity Partners AVI Global Trust JPMorgan European Smaller Companies Trust Schroder Investment Trust - Schroder AsiaPacific Fund International Biotechnology (LON:IBT) and abrdn Private Equity Opportunities (LON:APEO) are both small-cap financial services companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability. Which has more risk and volatility, IBT or APEO? International Biotechnology has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, abrdn Private Equity Opportunities has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Is IBT or APEO a better dividend stock? International Biotechnology pays an annual dividend of GBX 29 per share and has a dividend yield of 4.7%. abrdn Private Equity Opportunities pays an annual dividend of GBX 17 per share. International Biotechnology pays out 27.7% of its earnings in the form of a dividend. abrdn Private Equity Opportunities pays out 4,250.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio. Which has preferable earnings and valuation, IBT or APEO? abrdn Private Equity Opportunities has higher revenue and earnings than International Biotechnology. abrdn Private Equity Opportunities is trading at a lower price-to-earnings ratio than International Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInternational Biotechnology£41.82M5.28£37.91M£104.805.86abrdn Private Equity Opportunities£80.21M0.00£60.96M£0.40N/A Does the media refer more to IBT or APEO? In the previous week, International Biotechnology's average media sentiment score of 0.00 equaled abrdn Private Equity Opportunities'average media sentiment score. Company Overall Sentiment International Biotechnology Neutral abrdn Private Equity Opportunities Neutral Do institutionals and insiders hold more shares of IBT or APEO? 45.2% of International Biotechnology shares are held by institutional investors. Comparatively, 72.2% of abrdn Private Equity Opportunities shares are held by institutional investors. 4.2% of International Biotechnology shares are held by company insiders. Comparatively, 3.7% of abrdn Private Equity Opportunities shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is IBT or APEO more profitable? International Biotechnology has a net margin of 90.66% compared to abrdn Private Equity Opportunities' net margin of 76.01%. International Biotechnology's return on equity of 13.67% beat abrdn Private Equity Opportunities' return on equity.Company Net Margins Return on Equity Return on Assets International Biotechnology90.66% 13.67% 3.57% abrdn Private Equity Opportunities 76.01%5.18%3.35% SummaryInternational Biotechnology beats abrdn Private Equity Opportunities on 7 of the 12 factors compared between the two stocks. Get International Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBT vs. The Competition Export to ExcelMetricInternational BiotechnologyAsset Management IndustryFinancial SectorLON ExchangeMarket Cap£220.70M£1.25B£6.14B£2.97BDividend Yield4.20%4.37%4.18%5.02%P/E Ratio5.8621.9612.95151.20Price / Sales5.282,370.641,747.79252,273.63Price / Cash155.7460.81128.3627.97Price / Book0.801.221.914.55Net Income£37.91M£263.98M£1.23B£5.90B7 Day Performance3.43%0.63%0.97%1.80%1 Month Performance-0.58%2.85%3.26%4.52%1 Year Performance-5.48%6.82%16.51%79.93% International Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBTInternational BiotechnologyN/AGBX 614.40+2.7%N/A-6.9%£220.70M£41.82M5.86N/AHigh Trading VolumeAPEOabrdn Private Equity OpportunitiesN/AN/AN/AN/A£880.29M£80.21M1,435.00N/AMUTMurray Income TrustN/AGBX 875.07+0.1%N/A+0.1%£874.27M£97.96M9.64147,000Dividend CutESCTThe European Smaller Companies TrustN/AGBX 216+0.2%N/A+17.1%£851.99M£96.24M10.18305News CoveragePositive NewsTFIFTwentyFour IncomeN/AGBX 113.41+0.2%N/A+7.0%£848.90M£55.96M0.98N/ANews CoverageSLPEStandard Life Private Equity TrustN/AGBX 550flatN/A+0.4%£845.60M£251.60M3.54N/AMRCHThe Merchants TrustN/AGBX 566.05+0.2%N/A-3.4%£841.89M£119.93M7.73N/ANews CoverageInsider TradeNBPENB Private Equity PartnersN/AGBX 1,432flatN/A-11.9%£830.57M£12.90M-37.56N/AAGT.LNAVI Global TrustN/AN/AN/AN/A£812.93M£51.62M20.82N/AHigh Trading VolumeJESCJPMorgan European Smaller Companies TrustN/AN/AN/AN/A£795.72M£114.05M7.60N/ASDPSchroder Investment Trust - Schroder AsiaPacific FundN/AGBX 562-0.4%N/A+4.4%£793.92M£134.70M6.56N/A Related Companies and Tools Related Companies abrdn Private Equity Opportunities Competitors Murray Income Trust Competitors The European Smaller Companies Trust Competitors TwentyFour Income Competitors Standard Life Private Equity Trust Competitors The Merchants Trust Competitors NB Private Equity Partners Competitors AVI Global Trust Competitors JPMorgan European Smaller Companies Trust Competitors Schroder Investment Trust - Schroder AsiaPacific Fund Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:IBT) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding International Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share International Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
